As Redhill Biopharma Ltd. suggested it might move the needle on treating Helicobacter pylori (H. pylori) bacterial infection, the company's shares (NASDAQ:RDHL) sizzled, as well, hitting an historic high of $22.22 before closing Monday at $19.07 for a gain of $2.61, or 15.9 percent. Read More
Roche AG unit Genentech is placing a sizeable bet on the field of ubiquitin-specific protease (USP), "which is probably where kinases were 20 or 30 years ago," Tim Harrison, Almac Discovery Inc.'s vice president of discovery chemistry told BioWorld Today. Read More
As hordes converge on the 2015 Biotechnology Industry Organization (BIO) International Convention in Philadelphia, a question on the minds of many early stage innovators is how to stimulate more investment by venture capital (VC) firms in the costly and risk-fraught discovery sector. Read More
LONDON – The extent to which big pharma has piled into rare disease research is highlighted in a new study of patents in the field launched at the Biotechnology Industry Organization meeting on Monday. Read More
The true value of reslizumab, recognition of which helped Teva Pharmaceutical Industries Ltd. win its 2011 bid for Cephalon Inc., moved a step closer to being more widely known Monday as the FDA accepted Teva's biologics license application (BLA) for the potential therapy. Read More
HONG KONG – The discovery of a previously unknown autophagy defect associated with sarcopenia in mice could enhance the treatment or prevention strategies for managing the wasting condition in humans, suggest the findings of a study by Japanese researchers at Toyohashi University of Technology (TUT). Read More
Intrexon Corp., of Germantown, Md., and San Francisco-based Harvest Capital Strategies LLC, part of JMP Securities LLC, formed a new investment fund to back as many as 10 new companies a year leveraging Intrexon's suite of synthetic biology technologies. Read More
Actavis plc, of Parsippany, NJ, adopted Allergan plc as its new global name and began trading today under a new symbol, AGN, on the New York Stock Exchange. Read More
CTI Biopharma Corp., of Seattle, disclosed findings from an investigator-sponsored phase II trial in patients with either primary (de novo) acute myeloid leukemia (AML) or AML that has evolved from myelodysplastic syndrome. Read More
